Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | HC Chung, JA. Lopez-Martin, SCH Kao, WH. Miller, W Ros, B Gao, A Marabelle, M Gottfried, A Zer, JP Delord, N Penel, SI Jalal, L Xu, S Zeigenfuss, SK. Pruitt, SA Piha-Paul | ||||||||||||
Title | Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158 | ||||||||||||
|
|||||||||||||
URL | http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.8506 | ||||||||||||
Abstract Text | Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 8506-8506 DOI: 10.1200/JCO.2018.36.15_suppl.8506 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung small cell carcinoma | sensitive | Pembrolizumab | Phase II | Actionable | In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in superior objective response rate (35.7%, 15/24 vs 6.0%, 3/50), median progression-free survival (2.1 vs 1.9 months), and median overall survival (14.6 vs 7.7 months) in patients with CD274 (PD-L1)-positive (combined positive score>=1) advanced small cell lung cancer compared to patients with CD274 (PD-L1)-negative tumors (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 8506-8506; NCT02628067). | detail... |